1:22 The Immunological Impact of TP53 in Patients With MDS July 16, 2021 • AML Content Hub @ShahramKordasti, of @KingsCollegeLon, discusses the #immunological impact of TP53 mutations on #MDS #prognosis.
3:56 The Impact of Genetics on Treatment for Patients With MDS July 16, 2021 • AML Content Hub Valeria Santini, MD, University of Florence, Italy, discusses the #genomiclandscape of #MDS.
2:36 Earlier AML Detection June 16, 2021 • AML Content Hub @DrChrisHourigan, from @nih_nhlbi, discusses earlier #AML #detection and #measurable #residual #disease.
2:37 How to Manage Patients Progression From MDS to AML June 16, 2021 • AML Content Hub Andrew M. Brunner, MD, from @MGHMedicine, discusses #management of #progression from #MDS to #AML.
23:03 Diagnostic Principles for TP53-Mutant AML May 11, 2021 • AML Content Hub @JoeKhouryMD of @MDAndersonNews discusses #diagnosis of #AML with TP53 #mutations.
6:39 Treating AML After Evolution From MPD May 8, 2021 • AML Content Hub Raajit K. Rampal, MD, PhD, of @sloankettering, discusses #treatment for patients with #AML which has evolved from #myeloproliferative disease.
:42 Tomivosertib Exhibits Potent Anti-leukemic Properties on AML Cells May 7, 2021 • AML Content Hub Researchers from @LurieCancer and @nufeinbergmed present anti-leukemic properties of #tomivosertib as #therapy for #AML.
45:42 The Use of Intensive Treatment in Elderly Patients With AML May 1, 2021 • AML Content Hub @GOssenkoppele discusses #AML treatment in #elderly patients.
7:02 Venetoclax-based Regimens for Select Patients With AML April 27, 2021 • AML Content Hub James Foran, MD, of @MayoClinic, discusses key considerations for using #venetoclax in certain patients with #AML.
